Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Core Insights - Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing curative targeted cell therapies for autoimmune diseases [3] - The company will participate in the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 11:50 a.m. ET in Boston, MA [1] - A live webcast of the presentation will be available on the company's website, with replays accessible for 30 days [2] Company Overview - Cabaletta Bio is dedicated to advancing engineered T cell therapies that may provide deep and durable, potentially curative treatments for a variety of autoimmune diseases [3] - The company's lead strategy, CARTA, focuses on the development of rese-cel, a fully human CD19-CAR T cell investigational therapy containing 4-1BB [3] - Rese-cel is currently being evaluated in the RESET™ clinical development program, which spans multiple therapeutic areas including rheumatology, neurology, and dermatology [3]